# GenIV vaccines: bridging innovation to equity in neglected tropical diseases

## TL;DR

This paper explores how new vaccine technologies can help fight neglected tropical diseases by combining innovation with global equity strategies.

## Contribution

The paper introduces GenIV vaccines as a novel approach to address neglected tropical diseases through equitable global collaboration.

## Key findings

- GenIV vaccines show strong adaptability and immunogenicity, making them suitable for NTDs.
- Leishmaniasis is presented as a case study for applying GenIV vaccines through regional manufacturing.
- The paper emphasizes the importance of technology transfer and global collaboration for equitable vaccine access.

## Abstract

Recent breakthroughs in molecular vaccinology have defined a new generation of vaccines that integrate synthetic mRNA, self-amplifying RNA, and nanomaterial-based platforms. These fourth-generation vaccines offer exceptional adaptability, rapid design, and strong immunogenicity, as demonstrated during the COVID-19 pandemic. Their potential now extends to neglected tropical diseases (NTDs), where conventional vaccine strategies have failed to deliver durable protection. This review traces the evolution from whole-pathogen to precision molecular vaccines, highlighting the mechanisms, delivery systems, and translational advances that underpin the GenIV paradigm. Using leishmaniasis as a case study, we discuss how these technologies can bridge innovation and equity through technology transfer, regional manufacturing, and global collaboration. By integrating scientific, ethical, and implementation perspectives, this work outlines how next-generation vaccines can transform both epidemic preparedness and the equitable control of endemic diseases.